Abstract: Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.

Abstract: Provided herein are methods for treating nephrolithiasis and protecting the urothelium and inner lining of the kidney from thermal damage during lithotripsy by use of a thermosensitive bio-adhesive hydrogel. The described method dramatically improved the efficiency and effectiveness of stone clearance compared to conventional techniques while providing protection to the urothelium from potentially damaging temperature spikes.

Abstract: Provided herein are methods for treating nephrolithiasis and protecting the urothelium and inner lining of the kidney from thermal damage during lithotripsy by use of a thermosensitive bio-adhesive hydrogel. The described method dramatically improved the efficiency and effectiveness of stone clearance compared to conventional techniques while providing protection to the urothelium from potentially damaging temperature spikes.

Abstract: There are provided a connectable catheter system, device and methods of use thereof. The connectable catheter system, comprising: an intermediary catheter comprising an external section and a tip section, the tip section is configured to be inserted into a body of a subject; and a reconnectable indwelling stent comprising a connecting section and a target section, the target section being configured to be located within a body of the subject, wherein the connecting section of the reconnectable indwelling stent is configured to reversibly connect, within the subject body, to the tip section of the intermediary catheter to form a continuous conduit between the intermediary catheter and the reconnectable indwelling stent.

Abstract: Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.

Abstract: Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.

Abstract: Disclosed herein are materials, means and methods for sustained release of therapeutic agents for topical treatments. In particular, disclosed are means and methods for topical treatment of diseases of internal body cavities by embedding therapeutic agents in a slowly degrading biocompatible mixture applied to affected tissue.

Abstract: Described herein are compositions and methods for treating cancer of a body cavity, specifically urinary tract cancer, by way of a combination of at least two immunomodulatory agents, wherein one or more of the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.

Abstract: There are provided a connectable catheter system, device and methods of use thereof. The connectable catheter system, comprising: an intermediary catheter and a reconnectable indwelling stent wherein the intermediary catheter and the indwelling stent are configured to connect, within a subject body to form a continuous fluid conduit between the intermediary catheter and the reconnectable indwelling stent and to further allow controlled release of substances and/or heating of internal target regions.

Abstract: A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.

Abstract: A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.

Abstract: Apparatus and methods for treatment of an internal cavity are provided. The internal cavity is coated with a treatment solution. The treatment solution can include a solidifiable matrix with or without a drug or combination of drugs incorporated therein, or a drug solution without a solidifiable matrix. The treatment solution is coated onto at least a portion of the internal cavity, and acts as a slow-release drug delivery system.

Abstract: Provided herein are methods for treating cancer of a body cavity, including specifically urinary tract cancer, by way of at least one cell cycle regulator, and at least one anti-cancer drug for local treatment; wherein the therapeutic agents are embedded in, and slowly released from, a biocompatible hydrogel composition.

Abstract: A method is disclosed for production of a sterile thermoreversible hydrogel characterized by a known temperature Tmin at which the viscosity reaches at least a local minimum. In a preferred embodiment of the invention, the method comprises dissolving the components in water within ±4° C. of Tmin; forming the thermoreversible hydrogel; and filtering the thermoreversible hydrogel at Tmin. The final sterilization can be obtained by filtering under aseptic conditions or by autoclaving or irradiation of the final product. In other embodiments, the components of the gel are dissolved in a sufficiently large quantity of water that reduces the gel viscosity or precludes formation of a thermoreversible hydrogel, and sufficient water is then removed under vacuum to produce the final thermoreversible hydrogel.

Abstract: A hydrophilic biocompatible sustained-release material is disclosed. The material comprises amounts of Pluronic F-127, PEG-400, HPMC and water, effective to produce a composition of sufficiently low viscosity at room temperature to be injectable into an internal body cavity via a tube inserted within a urinary catheter. At body temperature, the material exhibits a much higher viscosity and will stably adhere to the internal surface of a body cavity. As the material dissolves, a therapeutic agent incorporated therein is slowly released to the body cavity, while the material itself is excreted from the body.

Abstract: Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: or a pharmaceutically acceptable salt, tautomer or hydrate thereof, where X2 is a bond or linker, X3 is bond or —PO4—, and X1, R1, R2, R3, and n are described herein. Also provided in some embodiments are methods for making and using such compounds and compositions.